Sanofi (NASDAQ:SNY) Shares Sold by Barrow Hanley Mewhinney & Strauss LLC

Barrow Hanley Mewhinney & Strauss LLC lowered its holdings in Sanofi (NASDAQ:SNY) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,697,289 shares of the company’s stock after selling 140,540 shares during the period. Sanofi comprises 1.3% of Barrow Hanley Mewhinney & Strauss LLC’s holdings, making the stock its 28th biggest holding. Barrow Hanley Mewhinney & Strauss LLC owned about 0.30% of Sanofi worth $371,240,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in SNY. Victory Capital Management Inc. boosted its position in shares of Sanofi by 27.6% in the 3rd quarter. Victory Capital Management Inc. now owns 8,669 shares of the company’s stock valued at $500,000 after purchasing an additional 1,876 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after acquiring an additional 33,105 shares during the period. Kingsview Wealth Management LLC raised its holdings in shares of Sanofi by 15.5% during the third quarter. Kingsview Wealth Management LLC now owns 5,901 shares of the company’s stock valued at $340,000 after acquiring an additional 794 shares during the period. Independent Advisor Alliance acquired a new position in Sanofi in the 3rd quarter worth approximately $202,000. Finally, Bank of Montreal Can grew its position in Sanofi by 10.0% during the 3rd quarter. Bank of Montreal Can now owns 256,438 shares of the company’s stock worth $14,784,000 after purchasing an additional 23,352 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Up 1.7 %

SNY opened at $55.82 on Friday. The company has a market capitalization of $141.66 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The business has a 50-day moving average of $55.13 and a 200-day moving average of $52.79.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target for the company. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.